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Abstract
Sarcopenia (loss of muscle mass/strength) burdens many older adults – hospitalised older adults being particularly vulnerable. Treating the
condition, protein supplementation (PrS) and resistance training (RT) may act synergistically. Therefore, this block-randomised, double-blind,
multicentre intervention study, recruiting geriatric patients > 70 years from three medical departments, investigated the effect of PrS combined
with RT during hospitalisation and 12 weeks after discharge. Participants were randomly allocated (1:1) to receive PrS (totally 27·5 g whey
protein/d, about 2000 kJ/d) or isoenergetic placebo-products (< 1·5 g protein/d) divided into two servings per d to supplement the habitual
diet. Both groupswere engaged in a standardised, progressive low-intensity RT programme for the lower extremities (hospital: supervised daily/
after discharge: self-training 4×/week). From April 2016 to September 2017, 2351 patients were screened, 462 were eligible, and 165 included.
Fourteen were excluded and ten dropped out, leaving 141 participants in the intention-to-treat analysis. The average total protein intake during
hospitalisation/after discharge was 1·0 (interquartile range (IQR) 0·8, 1·3)/1·1 (IQR 0·9, 1·3) g/kg per d (protein-group) and 0·6 (IQR 0·5, 0·8)/0·9
(IQR 0·6, 1·0) g/kg per d (placebo group). Both groups improved significantly for the primary and secondary endpoints ofmusclemass/strength,
functional measurements and quality of life, but no additional effect of PrS was seen for the primary endpoint (30-s chair stand test, repetitions,
median changes from baseline: (standard test: 0 (IQR 0, 5) (protein group) v. 2 (IQR 0, 6) (placebo group) andmodified test: 2 (IQR 0, 5) (protein
group) v. 2 (IQR −1, 5) (placebo group)) or any secondary endpoints (Mann–Whitney U tests, P> 0·05). In conclusion, PrS increasing the total
protein intake by 0·4 and 0·2 g/kg per d during hospitalisation and after discharge, respectively, does not seem to increase the adaptive response
to low-intensity RT in geriatric medical patients.
Key words: Sarcopenia: Older adults: Milk-based protein: Muscle strength: Muscle mass: Physical function: Rehabilitation
Sarcopenia is a progressive, generalised skeletal muscle disorder
characterised by the loss of muscle mass/quality and accompa-
nying muscle weakness. When the physical function is also
affected, sarcopenia is considered severe(1). Sarcopenia burdens
many older adults – prevalence differs widely depending on
the methods and definitions used(2), but up to 50 % of older
adults > 80 years are estimated to be affected by it(3). The pri-
mary cause of sarcopenia is age related, while secondary causes
are disease, nutrition or activity related(3,4). Only recently sarco-
penia has been recognised as an independent condition/
disease, by receiving its own International Classification of
Disease, Tenth Revision, Clinical Modification (ICD-10-MC)
Abbreviations: BIA, bio‐impedance analysis; CST, chair stand test; EWGSOP2, EuropeanWorkingGroup on Sarcopenia inOlder People; IQR, interquartile range;
LBM, lean body mass; mITT, missing intention to treat; MMSE, the Mini Mental State Examination; MPS, muscle protein synthesis; NRS, nutritional risk screening;
PP, per‐protocol; PrS, protein supplementation; RT, resistance training; VAS, visual analogue scale.
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code(5). The most recent consensus definition of sarcopenia
focuses on muscle strength as the key characteristic of sarcope-
nia to be used in the identification of people with the disease,
while measures of muscle mass/quality can be used confirma-
tively(1). Sarcopenia increases the risk of disability, morbidity,
hospitalisation and mortality(1,3,6–8) and is associated with
decreased quality of life(9) as well as increased healthcare
costs(6,10). Thus, identification of effective strategies to prevent
or counteract sarcopenia is highly relevant – especially in geriatric
patients who are particularly vulnerable, as they are likely to be
subject to all secondary causes of sarcopenia.
It has been shown that protein supplementation (PrS) alone
can improve parameters of muscle strength, muscle mass and
physical function in older adults(11–13). Also, PrS has been shown
to enhance the adaptive response to resistance training (RT)
interventions (mostly 6–12 weeks’ duration); however, not in
all studies(11,14–23). A hypothesis is that those who are most weak,
for example, frail and sarcopenic, or those having a low habitual
protein intake might benefit more from a combined intervention
of PrS and RT(11,13–16,19,22,24–26). Despite this, the evidence is
sparse in geriatric patients, many of whom are weak and mal-
nourished and with higher metabolic demands due to acute
and/or chronic inflammatory conditions(25). Thus, the aim of
the present study was to investigate whether PrS has any addi-
tional effects in a population of Danish geriatric medical patients
engaged in RT during hospitalisation and 12 weeks after dis-
charge, on parameters of muscle strength, muscle mass and
physical and mental function.
Subjects and methods
Ethics statement
The study was conducted in accordance with the principles
of the World Medical Association Declaration of Helsinki.
Approval was given by the Research Ethic Committee of
the Capital Region of Denmark (H-16018240), the Danish
Data Protection Agency (HGH-2016-050), and the study is
registered and available in the clinical.trial.gov database
(NCT02717819, registered 9 March 2016). Furthermore, a study
protocol has been published, verifying adherence to original
intent(27). Participants did not have any cost associated with par-
ticipation, and informed consent was signed before enrolment.
Study design and population
The study was a block-randomised, double-blinded, placebo-
controlled, multicentre intervention study. Patients were screened
consecutively by study investigators from three Medical
Departments of three different Hospitals in the Capital Region
of Denmark (Herlev, Gentofte, and Glostrup Hospital). Recruit-
ment took place within 72 h of admission. After inclusion and
baseline tests, participants were randomly allocated (1:1) to
receive either PrS or an isoenergetic placebo product, to supple-
ment habitual diet. Randomisation was performed in blocks of
20, according to the recruitment site, using sealed, opaque enve-
lopes containing papers with either an ‘A’ or a ‘B’. Participants,
hospital staff and study investigators were blinded towards the
randomisation. Both groups followed the same RT programme
and took daily vitamin D supplements. The intervention started
at the hospital after randomisation and lasted until 12 weeks after
discharge. All patients admitted to one of the three recruitment
sites, without planned transfer to other hospitals/departments,
were considered for the study. The eligibility criteria are sum-
marised in Table 1. The published study protocol can be referred
to for more details about the methods(27).
Intervention
Intervention products. Participants allocated to the protein
group received a protein-enriched, milk-based supplement
(Protino, Arla Foods®: 2120 kJ, 27·5 g protein (25 g whey/
2·5 g casein), 27·5 g fat, 37·5 g carbohydrate and 2·8 μg vitamin
D per 250 ml) (refer to the published study protocol, online
Supplementary Table S1 in Gade et al.(27), for amino acid profile
of the intervention product). Participants allocated to the pla-
cebo group received an isoenergetic placebo beverage (Arla
Foods®: 2108 kJ, 1·5 g protein, 26·9 g fat, 63·9 g carbohydrate per
250 ml) developed specifically for the present study. Both prod-
ucts were ready to drink, with a flavour of raspberry, and came in
white bottles with either an ‘A’ or ‘B’ label on the front.
Participants were instructed to drink 250ml intervention product
per d divided into two servings, leading to a total daily dose of
27·5 g protein in the protein group v. about 1·5 g protein in the
placebo group. While hospitalised, the participants had the sup-
plements served at breakfast and after the RT, mostly in the after-
noon. After discharge, participants were advised to have one
serving at breakfast and one serving with the next cold main
meal. However, consumption at any time was preferred over
not drinking the supplements because of specific timing con-
strictions. The participants were told to continue with their
habitual dietary intake, unless they were advised otherwise by
health care providers. Furthermore, to ensure comparable
intakes between groups, all participants were provided with
and instructed to take a daily vitamin D supplement of 20 μg,
as recommended by the Danish National Board of Health(28).
An exception was whether the serum levels at baseline were
≥100 nmol/l or when higher doses were prescribed. During
hospital admission, the vitamin D was handed out by nurses
or study investigators. Participants who consented had a daily
text message reminding them about study compliance.
Resistance exercise training programme. The RT programme
consisted of three exercises targeting the gluteal, quadriceps,
Table 1. Eligibility criteria for study participation
Inclusion criteria Exclusion criteria
Female or male Active cancer or terminal disease
Age ≥ 70 years Renal insufficiency*
Speak/understand Danish Cognitive impairment†
Expected length of stay > 3 d‡ Enteral or parenteral nutrition only
Independent stand function > 30 s Milk/lactose allergy/ intolerance
Plan of losing weight/special diet
Pacemaker§
* Estimated glomerular filtration rate< 30 ml/min per 1·73 m2.
† Not able to comprehend the purpose of the study/give informed consent.
‡ Evaluated by the medical staff at the department.
§ Due to bio-impedance analysis measurements.
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hamstring and calf muscles. The exercises were a bridging exer-
cise, a chair rise exercise and a heel raise exercise. A training ses-
sion consisted of three sets of each exercise, aiming for ten
repetitions, pursuing an intensity of 8–12 repetitions maximum.
The RT programme was adjusted after standardised procedures
to ensure progression (regression, if necessary). The exercises
existed in five different modes (A–B–C–D–E), graduated in terms
of increasing resistance, by applying the participants’ own body
weight and different starting positions (refer to the published
study protocol, online Supplementary Fig. S1 in Gade et al.(27),
for illustrated exercises). Daily supervised RT was offered in
addition to the standard care during hospital admission. After dis-
charge, the participants were encouraged to perform the same
RT programme four times per week as home-based self-training.
Furthermore, the participants received home visits by a physio-
therapist in study weeks 3, 6 and 9 and after discharge if read-
mitted. During these visits, the RT programme was supervised
and adjusted if needed.
Measures of compliance. During hospitalisation, the study
investigators and physiotherapists registered compliance to the
supplements, vitamin D and amount of RT performed (number
of sets and repetitions for each exercise and days with no RT).
After discharge, the participants were instructed to save all bottles
of the intervention product, both empty and full if non-compliant.
The bottles were picked up during home visits and simultane-
ously new supplies were also delivered. For those participants
discharged to a 24-h rehabilitation centre, an agreement with
the relevant staff was made, who handed out the supplements
and saved all bottles. Originally, participants were instructed to
register compliance (RT/intervention products/vitamin D) in a
‘study diary’, but for the vast majority (> 95 %) this was too high
a burden/workload for them to handle. Thus, this strategy was
abandoned, and it wasmade optional. Subsequently, compliance
with the RT and vitamin D was registered as detailed as possible
during the weekly phone call to participants, asking about the
overall compliance and any deviations. The average RT compli-
ance was categorised into one of five ordinal ‘activity categories’
(for definition of the categories refer to the online Supplementary
Table S1). Regarding vitamin D intake, if handed out (some
participants took vitamin D as part of a multivitamin tablet),
the number of tablets left in the bottlewas counted at the last visit.
Also, the content labels of the participants’medicine/vitamin bot-
tles were checked at home visits to ensure participants did not
receive too high amounts, or to register the total intake for those
participants prescribed higher amounts.
Outcome parameters
Baseline characteristics and endpoints were collected/measured
prior to randomisation and within 72 h of admission to the medi-
cal department. Endpoints were measured again within 72 h
after discharge (at the hospital or at home) and after 12 weeks
(± 2 d) (at home). Tests were performed in a predefined order
to reduce fatigue and 1.5–2 h after breakfast (sometimes 1.5–2 h
after lunch). Follow-up registration of admission to hospital,
length of stay(s) and mortality was made for 6 months after
the intervention period. All data were collected by study inves-
tigators and followed standardised procedures.
Baseline characteristics. Besides different participant charac-
teristics collected from the participants and the electronic patient
register, participants were screened for depression using the
Geriatric Depression Scale(29), screened for nutritional risk
according to nutritional risk screening (NRS-2002)(30) and cate-
gorised into ‘no sarcopenia, sarcopenia and severe sarcopenia’,
according to the revised definition from the European Working
Group on Sarcopenia in Older People (EWGSOP2) (using pro-
posed cut-off points for handgrip strength, appendicular skeletal
muscle mass index and gait speed)(1).
Primary endpoint. The 30-s chair stand test (30-s CST) is used
to measure muscle strength in the lower extremities, measured
using both a standardised and modified version(31,32). The num-
ber of times the participant could fully rise and sit from a standard
chair (height of 43–45 cm) in 30 s was counted, starting from a
sitting position. In the standard version, it was donewith the arms
folded across the chest, while in themodified version the use of the
armrests was allowed. Participants who could not stand from the
chair without using the arm rest got a score of zero in the standar-
dised version. Those participants only able to perform themodified
version at baseline, continued with that for the following assess-
ments; and if theywere able to do the standardised version as well,
it was performed after minimum 15 min of rest.
Secondary endpoints. Body composition variables were mea-
sured in kg for lean body mass (LBM) (total, arms, legs and
trunk), as a measure of skeletal muscle mass, as well as for total
fat mass. They were assessed by bio-impedance analysis (BIA)
(dual frequency (20 kHz, 100 kHz), tetra polar 8-Point Tactile
Electrode System (InBody-230)). Participants were wearing light
clothes and no shoes and were instructed to stand upright with
the feet on the build-in electrodes embedded in the scale plat-
form, to grasp the handles of the analyser while spreading the
arms as much as possible and to look straight ahead. Test–retest
reliability of the BIA for total LBMwas 98·4 (95 % CI 96·4, 99·6) %
(intra-class correlation coefficient 0·992 (95 % CI 0·988, 0·995)
(two-way mixed, absolute agreement method)), assessed in
the study population (duplicate measurements with reposition-
ing, n 93).
BMI (kg/m2) was calculated using the body weight measured
by the BIA equipment and the height of participants measured at
baseline with a stadiometer.
Handgrip strength was measured in kilogram with a DHD-1
digital hand dynamometer (Saehan Medical, 2012), using the
second handle position. The procedure recommended by
Roberts et al.(33) was used. Participants were asked to perform
three maximum force trials with their dominant hand, with 15-
s rest in between, and the highest value was registered.
Four-meter gait speedwas used to assess the usual gait speed
(m/s) over a short distance. The participants could use a gait aid,
which was registered, and the fastest of the two attempts was
recorded.
Daily functional ability was assessed by the Barthel-Index
(Barthel-100, modified)(34,35), which contains ten measures of
everyday and mobility activities scored by observation and clar-
ifying questions. A total of 100 points can be achieved, which
reflects full independence.
Mobility was assessed by De Morton Mobility Index, which
provides a fifteen-item unidimensional measure of mobility
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across the spectrum from bed bound to independent mobility.
A score from 0 to 100 can be achieved, where 100 represents
independent mobility(36).
Cognitive functioningwas assessed using the Danish version
of the Mini Mental State Examination (MMSE) questionnaire
(retroactive permission was obtained from Psychological
Assessment Resources ). It consists of small simple tasks to
elucidate eight different cognitive functions. A score from
0 to 30 can be achieved, where 30 represents the best/optimal
function(37).
Health-related quality of life was assessed using the generic
questionnaire, Euroqol EQ-5D-3L, which gives an index score as
well a visual analogue scale (VAS)(38) score. Prior permissionwas
obtained from the EuroQol Research Foundation.
Social support was evaluated asking participants about the
use of home care (yes/no, if yes, then divided into practical help,
personal care and both) and residence.
Use of gait aid was registered as yes (including specific gait
aid), no or cannot walk.
Admission to hospital and mortality was registered from the
electronic patient register. Admission to hospital was registered
regarding both the frequency and the total length of the hospi-
tal stay(s).
Other measures
Protein and energy intake and the habitual physical activity are
potential confounders. As such, these factors were measured in
conjunction with the study intervention as described below.
Additionally, the intervention products were evaluated by
participants.
Protein and energy intake. During hospitalisation, protein
(total g/d and g/kg per d) and energy (kJ/d) intake was
registered for up to 4 d depending on the length of stay.
Registration of food and drinks was done by study investigators
with help from the participants and nurses. For the period after
discharge, protein and energy intake was estimated based on an
average of four 24-h dietary recall interviews(39) performed at
home visits in study week 3, 6, 9 and 12 after discharge. A check-
list of specific food and beverages was used to verify the
reported intake, and picture series of portion sizes was used
to estimate portion sizes(40). For those participants who contin-
ued passively in the study, allowing the final assessment, the
24-hour dietary recall interviews (except for the final interview)
were done by phone and not during home visits. The software
program Madlog Vita® was used to estimate the total intake.
Habitual physical activity. A semi-structured interview was
used to assess the participants’ general activity levels (daily
activitiesþ exercise related) besides the RT programme, dividing
them into predefined ordinal categories from one to five,
inspired by Saltin & Grimby (1968)(41) (for definition of the
categories refer to online Supplementary Table S1). A total of
four interviews were performed in conjunction with the assess-
ment of protein and energy intake.
Product evaluation questionnaire. All participants evaluated
the intervention products at the final assessment or earlier if
dropping out of the study. Questions were directed towards both
liking of the product and possible side effects, even though none
was expected.
Statistics
Power calculation. The power calculation was based on the pri-
mary endpoint, the 30-s CST. To detect a clinical relevant differ-
ence of 2·0 number of stands(42) between groups, with an SD of
3·31 stands(31) (β = 80 % and α= 0·05, two sided), eighty partic-
ipants was required in each group, given an anticipated dropout
rate of 30 %(43,44) and 15 % non-compliance. The additional 15 %
was added to maintain statistical power in the per-protocol (PP)
analysis. For practical reasons, inclusion of 165 participants was
chosen (fifty-five from each site).
Statistical tests. The primary analysis was performed by the
intention-to-treat (ITT) principle, including everyone in the
group they were allocated to irrespective of study compliance,
but modified such that dropouts and those excluded after ran-
domisation were omitted from the analysis (no imputation tech-
niques formissing data, referred to asmITT in the following text).
Secondary analyses were also performed, including PP analysis
in those with high compliance only (defined in the present study
as an average intake ≥ 75 % of the intervention products, irre-
spective of the RT compliance) as well as the two sub-group
analyses with participants at nutritional risk and sarcopenic par-
ticipants, respectively. All analyses and tests were performed
according to a predefined data analysis plan(27). The groupswere
primarily compared looking at changes from baseline for the
entire intervention period but secondarily also looking sepa-
rately at changes during the period of hospitalisation (from base-
line assessments to discharge) and the 12-week period after
discharge. Distribution of the variables (parametric or non-
parametric) was determined from kurtosis and skewness [−1:1],
Shapiro–Wilk test > 0·05 and visual inspection of QQ plots.
According to distribution, continuous variables are presented
as medians and interquartile ranges (IQR) or as means and stan-
dard deviations or 95 % CI, and categorical variables as numbers
(absolute frequencies) and percentages. Statistical comparisons
were made between groups using the Mann–Whitney U test
(non-parametric distributions) or Student’s t test (parametric dis-
tributions) for continuous variables, and the χ2 test or Fisher’s
exact test (in case of expected cell count < 5) for the comparison
of categorical variables. Mann–Whitney U test was used for
comparison of ordinal variables. ANCOVA was used to compare
continuous, normally distributed outcomes between groups,
adjusting for confounding factors (baseline value, amount of
training during admission, length of hospital stay, total activity
for the period 12 weeks after discharge (not included when
looking at the hospitalisation period), energy (kJ/d) and protein
(g/d) from diet (adjusted to the specific time periods). Sensitivity
analysis, without outliers and with imputation techniques for
missing values, was part of the original data plan but not consid-
ered appropriate/necessary, due to no obvious incorrectness of
outliers and a low number of missing values. All tests were two
tailed, and an α level of P< 0·05 was used to determine statistical
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significance. All statistical analyses were performed using SPSS
Statistics v22 (SPSS Inc.).
Results
Recruitment lasted from 25 April 2016 to 11 September 2017,
with overlapping periods between sites. The last follow-up data
were collected on 15 June 2018. In total, 2351 patients were
screened, 462 met the eligibility criteria and 165 accepted to par-
ticipate. The flow of participants is illustrated in Fig. 1. Due to
slower recruitment rate than expected at some sites, the original
idea of an even distribution of participants from each site was
discarded and instead focus was on reaching the desired total
number of participants. A total of fourteen (8·5 %) participants
were excluded, primarily due to new cancer diagnosis. Only five
(6 %) participants in each group dropped out, primarily due to
medical/personal reasons unrelated to the study or due to the
heavy burden of the study intervention, primarily the RT.
However, some participants became inactive at some point dur-
ing the time of the intervention, but accepted the final assess-
ments, so they could be included in the mITT analysis. Three
of the dropouts withdrew during the hospitalisation period
and thus are not included in any of the analyses, but the other
seven dropouts are included in the analysis comparing the
groups during the hospitalisation period.
Baseline characteristics are presented in Table 2, and addi-
tional characteristics are available in the online Supplementary
Table S2. For the mITT analysis, the groups were comparable
at baseline for all measured characteristics and endpoints.
Also, for the PP analysis, including only those with a high com-
pliance (average intake ≥ 75 % of the intervention products for
Not included (n 2186)
One or two exclusion criteria (n 1197)
Not meeting inclusion criteria (n 692)
Declined to participate (n 297)
Δ Baseline to discharge (n 73)
Δ Discharge to 12 weeks after (n 70)
Δ Baseline to 12 weeks after discharge (n 70)§
Δ Baseline to discharge (n 61)
Δ Discharge to 12 weeks after (n 31)
Δ Baseline to 12 weeks after discharge (n 32)
Δ Baseline to discharge (n 75)
Δ Discharge to 12 weeks after (n 71)
Δ Baseline to 12 weeks after discharge (n 71)§
Δ Baseline to discharge (n 61)
Δ Discharge to 12 weeks after (n 29)
Δ Baseline to 12 weeks after discharge (n 30)
Analysis
Enrolment
Excluded (n 1)†
Drop-out (n 1)
Excluded (n 5)†
Drop-out (n 4)
Excluded (n 5)†
Drop-out (n 2)
Excluded (n 3)†
Drop-out (n 3)
Lost to follow-up
Received allocated intervention (n 82)Received allocated intervention (n 83)
Allocation
Assessed for eligibility (n 2351)
Randomised (n 165)
(n 73)
(Hospital admission(s) and mortality)
(n 75)
(Hospital admission(s) and mortality)
Intention-to-treat analysis
Per-protocol analysis||
Intention-to-treat analysis 
Per-protocol analysis||
During hospital admission*
During the 12 weeks after discharge‡
During hospital admission*
During the 12 weeks after discharge‡
Placebo group (n 82)Protein group (n 83)
6 months follow-up 6 months follow-up
Fig. 1. Participant flow chart. * Reasons for exclusion (n (protein group/placebo group): moved to another hospital/department or unusual course of diseasewith infection
(n 3/1), dead during hospitalisation (n 1/0), delirium (n 1/0). Reasons for drop-out (n (protein group/placebo group): no energy/capacity to continue (n 2/1). † Excluded
from all analyses. ‡Reasons for exclusion (n (protein group/placebo group): cancer (n 3/5). Reasons for drop-out (n (protein group/placebo group): no energy/capacity to
continue (n 2/0), no reasons given (n 1/3) and pain (n 0/1). § The primary analysis covering the entire intervention period. || Includes only participants who were highly
compliant (consumption of ≥75 % of the total dose of intervention product). Δ: Indicates analysis of changes.
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the total intervention period; protein group: n 32 v. placebo
group: n 30), the groups were comparable at baseline (results
not shown). The median duration of the study intervention
was similar between the groups for the mITT analysis (length
of hospitalisation: protein group: 5 (IQR 4, 8) d and placebo
group: 5 (IQR 3, 8) d, and the entire intervention period: protein
group: 89·5 (IQR 87, 92) d and placebo group: 89 (IQR 87, 92) d)
as well as for the groups in the PP analysis.
Compliance with intervention
Intervention products. The average compliance (intake in
percentage of total dosage) with the intervention products
during hospitalisation and following discharge was 87 (SD 19) %
and 62 (SD 32) % in the protein group and 88 (SD 18) % and
55 (SD 41) % in the placebo group, respectively. Subsequently,
for the whole intervention period the average compliance was
63 (SD 30) % and 57 (SD 39) % in the protein and placebo groups,
respectively. During hospitalisation, 84 % (n 61) in the protein
group and 81 % (n 61) in the placebo group were highly com-
pliant (intake ≥ 75 % of the total dose). Following discharge,
this dropped to 44 % (n 31) and 41 % (n 29) in the protein
and placebo groups, respectively. Thus, considering the entire
intervention period, 46 % (n 32) of the protein group and
42 % (n 30) of the placebo group were categorised as highly
compliant. Compliance between groups was not statistically
different.
No side effects were observed after consuming the interven-
tion products or after the RT. Some participants did in general
experience some discomfort, but this was highly correlated to
their acute condition or co-morbidities. Evaluation of the inter-
vention products at the end of the intervention period revealed
38 and 19 % in the protein and placebo groups, respectively,
though the products were highly or extremely satiating (n 135,
P= 0·016). In general, the study products were liked by the par-
ticipants, and 54 % in the protein group and 47 % in the placebo
group rated the liking as ‘a lot’ or ‘very much’ (n 134, P> 0·05).
However, 38 and 48 % in the protein and placebo groups,
respectively, experienced taste fatigue during the intervention
period, of which 16 and 14 % rated it as ‘often’ or ‘very often’
(n 133, P> 0·05).
Resistance training programme. During hospitalisation, there
were no differences in RT compliance or days with RT between
groups, and participants were almost fully compliant (Table 3).
Likewise, after discharge, no differences between groups were
observed for either the amount of home-based RT or other physi-
cal activities. About 51 % in both groups followed the RT pro-
gramme to a moderate to a high degree (Table 3). The same
picture was seen when looking only at those with a high com-
pliance to the intervention products in the PP analysis (results
not shown).
Average protein and energy intake
The average intake of protein (g/d and g/kg per d) and energy
(kJ/d) in the two groups is shown in Table 4. The amounts are
shown separately for dietary intake and intervention products as
well as a pooled total estimate, and intake is illustrated separately
for the period during hospital admission and the 12-week period
after discharge. No statistically significant differences were
observed between the groups for the dietary intakes.
Comparedwith the placebo group, the protein group had signifi-
cantly higher protein intake from the intervention products,
resulting in significantly higher total protein intake during hospi-
talisation and after discharge. Regarding energy intake from the
intervention products, the protein group had a significantly
higher energy intake during hospitalisation (however, only
0·02 %), but the energy intake from the intervention products
after discharge was similar between groups. Regarding the total
energy intake, this was not statistically different between groups
during hospitalisation or after discharge.
Primary endpoint
The results of the mITT analysis, for the primary endpoint 30-s
CST, are shown in Table 5. The only statistically significant
differences between the groups were for the 12-week period
after discharge, where more participants in the placebo group
improved (P= 0·042) and less had ‘no change’ in progression
(P= 0·023), and thesewere calculatedwith χ2 tests. For the entire
study period there was a tendency of more participants in the
placebo group with ‘no change’ in progression (P= 0·056).
However, considering the results for progression (improve, no
change or decline) as an ordinal variable, and analysing data
with theMann–WhitneyU test, all P values for the three time peri-
ods were non-significant. In the PP analysis, only tendencies
were found for progression (χ2 tests) (online Supplementary
Table S3). The protein group tended to have more participants
with improvement in the period of hospitalisation (protein
group: 71·7 % v. placebo group: 55·7 %, P= 0·069), but the pla-
cebo group tended to have more participants with improve-
ments in the period 12 weeks after discharge (protein group:
62·1 % v. placebo group: 82·8 %, P= 0·078). Looking at the entire
intervention period, more participants in the placebo group
tended to experience a decline in the 30-s CST (protein group:
3·2 % v. placebo group: 17·2 %, P= 0·053).
Secondary endpoints
The results of the mITT analysis for the secondary endpoints are
shown in Table 6. Looking at the period during hospitalisation,
no significant differences were observed between groups, but
there was a tendency to an increased Barthel score for the
placebo group (P= 0·052). During the 12-week period after dis-
charge, the placebo group had significantly higher improve-
ments in handgrip strength compared with the protein group
(P= 0·026). For the entire intervention period, no significant
differenceswere observed between the groups for any endpoint,
but there was a tendency to an increased Barthel score
(P= 0·097) and improved 4-m gait speed (P= 0·069) in the pla-
cebo group. In general, both groups improved for most end-
points when considering the total intervention period.
In the PP analysis (online Supplementary Table S2), no
differences were found between groups for the hospitalisation
period. The only difference between groups for the 12-week
period after discharge was a significantly higher increase
in BMI in the placebo group (median, protein group:
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0·44 (IQR −0·08, 0·88) kg/m2 v. placebo group: 1·00 (IQR 0·46,
1·43) kg/m2, P= 0·032), which was also evident when looking
at the entire intervention period (median, protein group: 0·19
(IQR −0·57, 1·04) kg/m2 v. placebo group: 0·88 (IQR 0·33,
1·50) kg/m2, P= 0·050). Also, considering the entire intervention
period, the placebo group exhibited a larger increase in 4-m gait
speed (median, protein group: 0·03 (IQR −0·11, 0·23) m/s v. pla-
cebo group: 0·20 (IQR 0·08, 0·33) m/s, P= 0·026) and had a
significantly higher increase in Barthel score (median, protein
group: 13 (IQR 2, 21) v. placebo group: 21 (IQR 9, 39),
P= 0·033). Furthermore, the total LBM tended to increase more
in the placebo group (median, protein group: 0·40 (IQR −3·20,
1·90) kg v. placebo group: 1·70 (IQR −0·50, 5·40) kg,
P= 0·052).
Admission to hospital, length of stay and mortality during
the study and follow-up. For the mITT analysis, the results
for (re)admission to hospital, total length of stay(s) and mortality
are shown in Table 7, both during the 12-week period after dis-
charge and for the 6-month follow-up after the study interven-
tion ended. There were no change between groups except for
mortality in the follow-up period, where significantly more par-
ticipants died in the protein group (P= 0·032). Reasons for dying
are given in the table note and considered to be unrelated to the
study interventions.
In the PP analysis, looking into the total length of stay as an
average of all (re)admissions, during the entire intervention
period, the protein group was admitted significantly longer than
the placebo group (median, 11·5 (IQR 5, 17) d v. 3 (IQR 1, 3) d,
Table 2. Baseline characteristics by treatment group*
(Numbers and percentages; mean values and standard deviations; medians and interquartile ranges (Q1, Q3))
Protein Placebo
n % n % Protein n/placebo n P
Number of females 51 69·9 49 65·3 73/75 0·556
Number of males 22 30·1 26 34·7
Age (years) 73/75 0·280
Mean 85·3 84·2
SD 6·2 6·3
BMI (kg/m2) 73/75 0·393
Mean 25·1 25·8
SD 4·2 5·2
Geriatric depression scale (0–15) 72/75 0·695
Mean 4·3 4·1
SD 3·1 3·0
SMI (kg total muscle/m2) 73/73 0·983
Median 8·5 8·4
Q1, Q3 7·7, 9·6 7·5, 10·1
CRP (mg/l) 71/73 0·864
Median 29 29
Q1, Q3 7, 62 2, 77
Admission diagnosis 73/75 0·546
Fall 9 12·3 13 17·3
Vertigo 5 6·8 7 9·3
Infection 17 23·3 22 29·3
Dehydration/electrolyte fluctuations 4 5·5 3 4·0
Causa socialis 7 9·6 10 13·3
Pain 13 17·8 10 13·3
Other† 18 24·7 10 13·3
Co-morbidities‡ 73/75
None 20 27·4 24 32·0 0·540
COPD 13 17·8 7 9·3 0·132
Cardiovascular 34 46·6 39 52·0 0·509
Diabetes mellitus 9 12·3 12 16·0 0·522
Other 17 23·3 22 29·3 0·404
Polyfarmaci (≥4 medications) 67 91·8 70 93·3 73/75 0·719
Serum vitamin D3 (nmol/l) 65/66 0·953
≥100 20 30·8 20 30·3
50–99 34 52·3 36 54·5
< 50 11 16·9 10 15·2
Nutritional risk (NRS-2002≥3) 15 20·5 25 33·8 73/74 0·071
EWGSOP2 sarcopenia classification 73/73
Sarcopenia 20 27·4 20 27·4 1·000
Severe sarcopenia 18 24·7 17 23·3 1·000
SMI, skeletal muscle index; Q1, first quartile; Q3, third quartile; CRP, C-reactive protein; COPD, chronic obstructive pulmonary disease;
NRS-2002, Nutritional Risk Screening-2002; EWGSOP, European Working Group on Sarcopenia in Older People.
* Statistical tests: χ2/Fisher’s exact test (counts< 5) (n and %), Students’ t test (mean and SD) and Mann–Whitney U test (median and Q1, Q3).
† ‘Other’ mostly includes cardiovascular problems, dysregulated medication, dyspnoea, syncope.
‡ Patients can be reported under several categories, but only once under each. ‘Other’ mostly includes osteoporosis and arthritis.
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P= 0·014). However, looking at the 6-month follow-up period,
the picture changed, and the participants in the protein group
were admitted for a significantly shorter period (median, 4·5
(IQR 3, 6·5) v. 9 (IQR 7, 14) d, P= 0·032). No differences were
found with respect to (re)admission or mortality.
Residence, home care and use of gait aids. These variables
were only compared for changes occurring throughout the entire
intervention period, as these changes take some time to mani-
fest. Most participants in both groups were admitted from own
house/apartment (protein group: 91·4 % v. placebo group:
Table 3. Resistance training (RT) and physical activity throughout the study period between groups*
(Medians and interquartile ranges (Q1, Q3); mean values and 95 % confidence intervals; numbers and percentages)
Protein group Placebo group
n % n %
RT, during the hospital admission (n) 73 75
RT (rounds/d, 0–9)†
Mean 6·80 7·11
95 % CI 6·2, 7·4 6·6, 7·6
Days with RT of total LOS (%)
Median 100 100
Q1, Q3 76, 100 78, 100
RT, 12 weeks after discharge‡ (n) 70§ 71§
1: No or very small amount of training 17 24·3 18 25·3
2: Small amount of training 17 24·3 17 23·9
3: Moderate amount of training 6 8·6 8 11·3
4: Regular amount of training 18 25·7 20 28·2
5: High amount of training 12 17·1 8 11·3
Physical activity besides RT, 12 weeks after discharge‡ (n) 70§ 71§
1: No or very little activity 14 20·0 17 23·9
2: Little activity 30 42·9 31 43·7
3: Moderate activity 16 22·9 13 18·3
4: Regular activity 10 14·3 10 14·1
5: High amount of activity 0 0·0 0 0·0
LOS, length of hospital stay; Q1, first quartile; Q3, third quartile.
* Statistical tests:Mann–WhitneyU test (median andQ1,Q3), Student’s t test (mean and 95%CI) and χ2/Fisher’s exact test (counts< 5) (n and%).
None of the tests was significant (P> 0·05).
† Based on daily records of the RT performed. Daily target was three exercises, three sets with ten repetitions. One round: ≥5 repetitions of an
exercise. Day of discharge not used to calculate the average.
‡Average estimates based on 4× activity interviews, covering the last week, every 3 weeks (average of three interviews (n 9), one interview (n 2)).
§ Drop-outs not included.
Table 4. Average protein and energy intake during hospitalisation and after discharge, by treatment group
(Medians and interquartile ranges (Q1, Q3))
During the hospital admission† During the 12 weeks after discharge†
Protein Placebo Protein Placebo
Median Q1, Q3 Median Q1, Q3 Median Q1, Q3 Median Q1, Q3
From the diet‡ (n) 70 74 70 71
Protein (g/d) 42 36, 52 42 30, 52 54 43, 64 56 44, 68
Protein (g/kg§ per d) 0·6 0·5, 0·8 0·6 0·5, 0·8 0·8 0·7, 1·0 0·8 0·6, 1·0
Energy (MJ/d) 5·3 4·4, 6·2 5·1 3·7, 6·0 5·4 4·8, 6·8 5·8 4·9, 7·2
From PrS|| (n) 73 75 70 71
Protein (g/d) 26 22, 28 1·4* 1·3, 1·5 19 10, 24 1·0* 0·1, 1·4
Protein (g/kg§ per d) 0·4 0·3, 0·4 0·0* 0·0, 0·0 0·3 0·1, 0·4 0·0* 0·0, 0·0
Energy (MJ/d) 2·0 1·7, 2·1 2·0** 1·8, 2·1 1·4 0·8, 1·9 1·4 0·1, 1·9
Total intake (n) 70 74 70 71
Protein (g/d) 68 56, 79 43* 31, 54 72 57, 81 56* 44, 69
Protein (g/kg§ per d) 1·0 0·8, 1·3 0·6* 0·5, 0·8 1·1 0·9, 1·3 0·9* 0·6, 1·0
Energy (MJ/d) 7·3 6·1, 8·3 6·9 5·4, 7·9 6·9 6·1, 7·8 7·5 5·6, 8·9
Q1, first quartile; Q3, third quartile; PrS, protein supplementation.
* P< 0·0001, ** P< 0·05 (Mann–Whitney U test).
† Drop-outs not included.
‡ Hospital: estimated by daily records for up to 4 d (n 87) (average of 3 d (n 27), average of 2 d (n 22), 1 d (n 8), due to early discharge, missing (n 4)). After discharge, average intake
estimated by means of 4× dietary interviews (n 131) every 3 weeks (average of three interviews (n 9), one interview (n 1)).
§ Hospital: calculated with baseline body weight as a reference. For 12 weeks after discharge: calculated with an average of post-discharge and final body weight as a reference. If
values are missing, then it is calculated from the remaining measure.
|| Hospital: calculated from daily records. For 12 weeks after discharge: calculated based on the collection of empty bottles and participants’ study product diaries (average of total
intake divided by the respective study periods).
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97·2 %). At the end of their intervention period, a couple of par-
ticipants in both groups had moved to a nursing home/sheltered
housing (protein group: 4·3 % v. placebo group: 2·8 %,
P= 0·681). The number of participants receiving help/any kind
of home care increased during the intervention period in both
groups (protein group: 61·4 to 71·4 % (P= 0·210) and placebo
group: 63·4 to 74·6% (P= 0·147)) but were not different between
groups (P= 0·807). Despite an increasing need for help, a
decrease in the number of participants who needed gait aids dur-
ing the intervention period was found in both groups, without
differing between groups (protein group: 71·4 to 60·0 % and pla-
cebo group: 80·3 to 63·4 %, P= 0·352). The primary gait aid used
in both groups was a walker, followed by a walking stick. The
PP analysis overall had the same findings (results not shown).
ANCOVA for primary and secondary endpoints
The test prerequisites were met only for the endpoints: 30-s CST-
modified, handgrip strength, MMSE and quality of life-VAS (mITT
analysis). A significant difference was seen only for handgrip
strength, during the 12-week period after discharge, in favour
of the placebo group (median, protein group: 0·25 (IQR −0·61,
1·11) and placebo group: 1·55 (IQR 0·68, 2·42), P= 0·039), and
this finding was the same as in the unadjusted mITT analysis.
Subgroup analysis
The number of participants at nutritional risk (NRS-2002(30)) at
baseline was 15 and 25 in the protein group and placebo group,
respectively. The sub-group analysis, including only these par-
ticipants, did not result in any significant differences.
Both in the protein and placebo group, twenty participants
were classified as sarcopenic at baseline, Of these, eighteen
and seventeen participants were considered severely sarcopenic
in the protein and placebo group, respectively (EWGSOP2 def-
inition(1). Also, subgroup analysis including these participants
did not result in any significant differences between groups.
Discussion
The present study did not find additive effects on any endpoints
of PrS in acutely ill hospitalised older adults offered standardised
Table 5. Results for the primary endpoint, changes in performance between groups, modified intention-to-treat analysis*
(Medians and interquartile ranges (Q1, Q3); numbers and percentages)
Protein group Placebo group
Baseline
test
Δ†
Baseline
to
discharge‡
Δ
Discharge
to 12
weeks
after
Δ
Baseline
to 12
weeks
after
discharge
Baseline
test
Δ Baseline
to
discharge‡
Δ
Discharge
to 12
weeks
after
Δ
Baseline
to 12
weeks
after
discharge P§ P|| P¶ P **
30-s CST std. (no. of
stands††)
0·707 0·954 0·164 0·226
Median 0 0 0 0 0 0 1 2
Q1, Q3 0, 8 0, 1 0, 3 0, 5 0, 6 0, 2 0, 6 0, 6
n, analysis 73 71 66 67 75 75 71 71
30-s CST mod. (no. of
stands††)
0·701 0·322 0·892 0·697
Median 6 1 0 2 5 1 1 2
Q1, Q3 3, 8 0, 3 −1, 3 0, 5 3, 7 −1, 3 0, 3 −1, 5
n, analysis 44 37 33 35 45 41 34 33
30-s CST progression
Improvement – – – 0·348 0·042 0·664
n 47 40 48 44 53 51
% 66·2 60·6 70·6 58·7 76·8 73·9
No change – – – 0·895 0·023 0·056
n 10 9 12 10 2 5
% 14·1 13·6 17·6 13·3 2·7 7·2
Decline – – – 0·241 0·450 0·250
n 14 17 8 21 14 13
% 19·7 25·8 11·8 28·0 18·7 18·8
n, analysis 71 66 68 75 69 69
Stand, no use of arms 0·973 0·143 0·073 0·480
n 29 2 8 11 30 −1 17 15
% 39·7 2·8 12·1 16·4 40·0 −1·3 23·9 21·1
n, analysis 73 71 66 67 75 75 71 71
CST, chair stand test; std, standard (arms crossed across the chest); Q1, first quartile; Q3, third quartile; mod, modified (use of help, e.g. arm rest).
* Statistical tests: Mann–Whitney U test (median and Q1, Q3) and χ2/Fisher’s exact test (counts < 5) (n and %).
† Δ: indicates changes.
‡ Duration in days (median and Q1, Q3): protein group (5 and 4, 8) d and placebo group (5 and 3, 8) d.
§ P values for differences between groups at baseline (upon admission to hospital).
|| P values for differences in changes in performance between groups during the period of hospitalisation.
¶ P values for differences in changes in performance between groups during the 12-week period after discharge.
** P values for differences in changes in performance between groups for the entire study intervention period.
†† No differences between groups in height of chair at any time point (average height= 44·81 cm).
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Table 6. Results for the secondary endpoints, changes in performance between groups, modified intention-to-treat analysis*
(Medians and interquartile ranges (Q1, Q3))
Protein group Placebo group
Baseline
test
Δ† Baseline
to discharge‡
Δ Discharge
to 12 weeks
after
Δ Baseline to 12
weeks after
discharge
Baseline
test
Δ Baseline to
discharge‡
Δ Discharge
to 12 weeks
after
Δ Baseline to 12
weeks after
discharge P§ P|| P¶ P **
Body composition††
Total LBM (kg) 0·721 0·332 0·803 0·716
Median 44·0 −0·3 0·9 0·8 42·5 −0·1 0·8 0·9
Q1, Q3 36·6, 49·9 −2·1, 0·8 −0·2, 3·2 −1·5, 3·3 38·6, 52·2 −1·3, 0·8 −0·7, 2·6 −0·6, 2·8
LBM arms (kg) 0·932 0·117 0·415 0·790
Median 4·7 −0·1 0·0 0·0 4·3 −0·05 0·0 −0·1
Q1, Q3 3·4, 5·4 −0·4, 0·0 −0·2, 0·4 −0·5, 0·3 3·6, 5·8 −0·2, 0·1 −0·2, 0·3 −0·4, 0·2
LBM legs (kg) 0·489 0·979 0·206 0·319
Median 12·2 0·2 0·5 0·8 11·8 0·1 0·7 1·0
Q1, Q3 9·0, 14·3 −0·3, 0·7 −0·2, 1·1 0·0, 1·5 9·9, 15·3 −0·2, 0·7 0·1, 1·4 0·3, 1·5
LBM torso (kg) 0·913 0·246 0·622 0·960
Median 19·1 −0·2 0·2 0·05 19·6 −0·2 0·1 −0·2
Q1, Q3 16·1, 22·3 −0·9, −0·2 −0·4, 1·0 −1·1, 0·7 16·5, 22·6 −0·6, 0·3 −0·5, 0·8 −0·9, 0·7
Total FM (kg) 0·450 0·437 0·454 0·730
Median 21·6 0·1 −0·3 0·2 24·9 0·1 −0·05 −0·4
Q1, Q3 16·5, 28·4 −0·7, 1·2 −−2·2, 1·4 −2·0, 1·5 16·3, 31·5 −0·8, 1·0 −2·3, 2·3 −2·5, 1·6
n, analysis 72 69 64 66 72 66 60 61
BMI (kg/m2) 0·508 0·554 0·528 0·600
Median 25·3 −0·08 0·4 0·2 25·1 0·04 0·5 0·5
Q1, Q3 22·3–27·0 −0·4, 0·3 −0·2, 0·9 −0·5, 1·0 21·7, 30·0 −0·4, 0·3 −0·3–1·2 −0·5, 1·0
n, analysis 73 70 66 69 75 74 65 66
Handgrip strength (kg) 0·977 0·681 0·026 0·115
Median 17·8 0·2 0·1 0·44 17·7 −0·3 1·4 0·7
Q1, Q3 13·3, 23·3 −1·9, 1·6 −2·3, 2·4 −2·8, 1·8 13·1, 22·7 −2·2, 2·3 −0·7, 3·5 −1·8, 4·0
n, analysis 73 72 69 70 75 75 68 68
DEMMI (0–100) 0·763 0·994 0·525 0·510
Median 53 4 3·5 9 53 5 5 10
Q1, Q3 44, 67 0, 12 −4, 14 0, 20 44, 62 −3, 9 −1, 18 0, 22
n, analysis 73 71 68 69 75 75 70 70
4-m gait speed (m/s) 0·055 0·481 0·193 0·069
Median 0·6 0·0 0·1 0·05 0·5 0·0 0·1 0·2
Q1, Q3 0·5, 0·9 −0·1, 0·1 −0·1, 0·2 −0·1, 0·2 0·4, 0·7 −0·1, 0·2 −0·05, 0·3 −0·1, 0·4
n, analysis 73 71 65 67 75 72 65 66
Barthel (0–100) 0·119 0·052 0·985 0·097
Median 79 10 0 15 76 19 0 20
Q1, Q3 68, 93 2, 24 −2, 8 5, 24 58, 87 4, 30 −1, 7 6, 32
n, analysis 68 67 69 65 71 71 71 67
MMSE score (0–30) 0·666 0·958 0·152 0·457
Median 26 1 0 1 26 0 −1 0
Q1, Q3 24, 28 −1, 2 −1, 2 0, 2 23, 28 −1, 3 −1, 1 −1, 3
n, analysis 73 72 69 69 75 75 70 70
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RT during admission and 12 weeks after discharge. However,
both groups improved significantly for most parameters, and
specifically the increase in LBM shows an adaptive response
to the RT in agreement with the previous studies(11,14–19,22–24)
and established knowledge(45). The placebo group generally
improved more than the protein group, which is unexpected,
as most systematic reviews and meta-analysis find additional
effects of PrS(11,14,17–19,23), with only a few finding no effects(15,24)
or conflicting results(16,21,22). However, regarding previous stud-
ies, it is hard to compare them directly as the study designs are
very heterogenous. Also, only a minority report the total
protein intake or activity besides the RT, which are known con-
founders. Furthermore, no one has to our knowledge included
very old geriatric medical patients. The two sub-group analyses
comparing only those at nutritional risk and those who were sar-
copenic at baseline also did not find any significant differences
between groups, despite the hypothesis of a higher benefit from
PrS. However, the statistical power was low, and generally the
effect of RT and/or general recovery from illnessmay have domi-
nated. Post hoc, observational analysis revealed that total physical
activity (RTþ habitual activity) was significantly correlated to
improvements in most end points (ANCOVA, results not shown).
Regarding mortality, significantly more patients in the protein
group died during the 6-month follow-up period (Table 7), but
this is considered a spurious finding unrelated to study participa-
tion. Most died while admitted to hospital with pneumonia or uri-
nary infection,which are on the top three of themost encountered
diagnoses in Danish geriatric medical patients(46). Furthermore,
the mortality rate was much lower than expected for the present
study population(47,48), and potential confounding factors were
not monitored in the follow-up period.
During hospitalisation, the protein group received on aver-
age 1·0 g protein/kg per d from the diet and PrS, and the placebo
group received 0·6 g protein/kg per d, which for both groups is
lower than the recommendation for acutely ill older adults of
1·2–1·5 g/kg per d(49). After discharge the intake increased to
1·1 g protein/kg per d in the protein group, being within the rec-
ommended range of intake for healthy older adults (withoutmal-
nutrition) of at least 1·0–1·3 g/kg per d(49,50). These said,
generally dietary requirements are probably higher for geriatric
patients than for healthy older adults in the period right after dis-
charge, as lose in LBM needs to be recovered(50) and stress
metabolism may persist for a little while. Also, 27 % of partici-
pants were screened to be at risk of malnutrition at admission,
likewise increasing requirements to enable gain in LBM. In com-
parison, the placebo group received 0·9 g protein/kg per d after
discharge, which was significantly lower compared with the pro-
tein group and below protein recommendations. However,
despite being statistically significant, the difference in protein
intake between the groups was small (0·2 g/kg per d) due to
the low compliance with study supplements. A large meta-analy-
sis, including adults performing regularly RT, showed a linear
dose–response relationship between the total daily protein intake
and increases in LBM, until a break point of 1·6 g/kg per d(17) was
achieved. Acute feeding/metabolic studies in older adults have
also shown a saturable linear dose–response relationship between
per-meal protein intake and post-prandial muscle protein synthe-
sis (MPS)(51–53), with a threshold of 0·40 (SD 0·19) g/kg per meal(52).Ta
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Based on the latter finding, it is hypothesised that the daily dis-
tribution of the total protein intake might have an independent
anabolic influence, even though the most optimal distribution
pattern is debated. One theory is that a balanced protein
distribution, where the protein intake in main meals reaches
the threshold for maximal MPS, is the most optimal(54–56).
However, arguments also exist that a protein intake beyond this
plateau continues to be beneficial, as the net anabolic effect
increases due to the suppression of muscle protein break-
down(54). Nevertheless, considering the total daily protein
intake in the protein group of about 67 g, this is far below
the 1·6 g/kg per d threshold, which also makes it less likely that
they reached the maximal threshold for the meals (equal to 26·6
(SD 5·6) g protein, based onbaseline bodyweight). Consequently,
due to the linear dose–response relationship of MPS until reach-
ing the thresholds for both per-meal and total daily protein intake,
any increase in protein intake should, theoretically, be beneficial.
This expectation is strengthened by the fact that RT sensitises
muscles to amino acids(57). However, the present study illustrates
that a difference in total protein intake of 0·4 g/kg per d during
hospitalisation and 0·2 g/kg per d after discharge, when simulta-
neously following a low-intensity/volume RT program, is not
enough to elicit a measurable and clinically meaningful change
in outcome variables between groups. Looking only at the partic-
ipants having high compliance with supplements, the difference
in total protein intake was 0·4 g/kg per d during hospitalisation
and 0·3 g/kg per d after discharge. However, the PP analysis
did not change the conclusions considerably, but the statistical
powerwas also lower. A studywitholder hospitalised adults given
PrS (24 g/d) and RT or RT only showed positive effects of PrS dur-
ing the length of hospital admission which was > 20 d for both
groups(58). Thus, the short length of hospital stay for all partici-
pants in the present study (median of 5 d) may have blunted
the chance of finding positive effects of the greater difference
in protein intake between groups looking only at the hospitalisa-
tion period. In relation to protein distribution/timing theories, the
consumption of smaller amounts of protein throughout the whole
day in the present study population might also have influenced
the outcomes.
Previously, it has been found that the sensitivity of muscle to
PrS increases with the duration, frequency and volume of RT(59).
In that perspective, our 12-week intervention period might have
been too short to allow for a significant additional effect of PrS, or
our home-based RT programme might have been performed
with too low intensity or the RT compliance was too low
(Table 3). Furthermore, research indicate that resistance-trained
individuals benefit more from PrS during RT compared with the
untrained individuals(17,59,60), and the participants in the present
study were not pre-conditioned to RT. Also, the fact that the pla-
cebo group received isoenergetic supplements may have
blunted the chance of finding significant effects of PrS, as suffi-
cient energy intake can preserve LBM and is a prerequisite for
ingested protein to be available for MPS(61,62). The energy intake,
RT and outcomes were increased or improved in both groups by
Table 7. Admission to hospital, length of stay and mortality between groups*
(Medians and interquartile ranges (Q1, Q3); numbers and percentages)
Protein group Placebo group
n % n % P
During the 12 weeks after discharge (n) 73 75
Mortality† 0 0 0 0 1·000
Admission to hospital 0·287
No. of admissions 53 72·6 60 80·0
One admission 16 21·9 12 16·0
Two admissions 2 2·7 3 4·0
Three admissions 2 2·7 0 0·0
Total LOS (d)‡ 0·591
Median 6·5 6
Q1, Q3 5, 16 3, 17
Days before one admission 0·934
Median 23 27
Q1, Q3 4, 49 13, 35
6 months after study intervention (n) 73 75
Mortality† 7 9·6 1 1·3 0·032
Admission to hospital 0·634
No. of admissions 47 71·2 53 71·6
One admission 17 25·8 17 23·0
Two admissions 1 1·5 3 4·1
Three admissions 1 1·5 1 1·4
Total LOS (d)‡ 0·154
Median 5 9
Q1, Q3 3, 12 5, 14
LOS, length of stay; Q1, first quartile; Q3, third quartile.
*Statistical tests: Mann–Whitney U test (median and Q1, Q3 and n and % (the latter analysed as continuous variables)).
†When a participant dies, the hospital submission(s) and LOS are not registered. Reasons for dying: protein group: urosepsis (n 2),
pneumonia (n 2), haematoma (n 1), unknown (n 2, but latest admission to hospital due to urosepsis (n 1), pneumonia (n 1)).
Placebo group: unknown (n 1, but latest admission to hospital due to pneumonia, with findings of a lung tumour).
‡ For all admissions in the time interval.
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the intervention, and perhaps the independent effect of energy
supplementation/meeting energy requirements in the context of
RT deserves more attention in future studies. For example, in the
opposite scenario, one could fear that an energy deficit during
RT would impair convalescence after RT and, in the worst case,
be detrimental. Confounding factors, known and unknown,
explaining the unexpected, more favourable effects in the pla-
cebo group, cannot be ruled out. Especially, differences in
recovery from the acute illness and/or co-morbidities may have
greatly influenced study conclusions. Block randomisation
according to recruitment site was chosen to eliminate potential
bias related to, for example, specific hospital care and residence/
municipality. No statistically significant differences were seen for
any of the measured confounders. However, the median total
energy intake in the placebo group was a little higher during
the 12 weeks after discharge, which was related to a non-
significantly higher dietary energy intake (Table 4). This higher
dietary intake may be associated with the lower satiety rating of
the supplements in the placebo group. Likewise, the RT amount
during admissionwas a little higher in the placebo group, though
not statistically significant (Table 3). Also, baseline characteristics
were not statistically different between groups. However, in an
observational analysis, exploring the factors that had influence
on changes from baseline, besides the amount of total activity
(RT þ habitual activity), a low baseline value was found to be
significantly associated with higher improvements for most end-
points, and the placebo group was at a lower baseline level than
the protein group for the endpoints shown to be significant in
either the mITT or PP analyses. Thus, overall randomisation
might not have been successful, and results may have been
biased. Not the least, because of test multiplicity, caution must
be shown not to overinterpret these findings.
The present study has limitations, some of which are dis-
cussed in the published study protocol, for example, the use
of BIA to measure LBM(27). Also, supervised RT lead to higher
RT compliance in previous studies(16). However, many geriatric
patients find it very burdensome to leave their homes, and, there-
fore, self-training at home was chosen. The use of 24-h recall
interviews in estimating dietary protein and energy intake was
chosen to minimise the study burden but is criticised for under-
estimating intake – especially carbohydrate-rich foods(63).
However, calculating the participants’ basal metabolic rate
(original Harris–Benedict equation) and estimating the activity
factor (protein group: 1·37 (SD 0·26) and placebo group: 1·31
(SD 0·36)), while taking into account the increase in body weight
and self-reported RT and activity level (Table 3), the reporting
seems very reasonable. The greatest limitation is considered to
be the low compliance to the supplements, which diminishes
the strength of the low rate of exclusions/dropouts and high
study power. It was the general experience that poor health,
including disease- and age-related anorexia, was the major rea-
son. Therefore, a higher dose of PrS would probably not have
increased the actual protein intake from the supplements and
subsequently resulted in a greater difference in protein intake
between groups. The compliance might have been higher if
the PrS had come in different flavours, as some participants also
reported taste fatigue. However, to significantly increase compli-
ance/total protein intake in a population of geriatric medical
patients, many of whom have low appetite and are malnour-
ished(25,64), a more holistic approach might be necessary.
Thus, future studies, focusing on PrS in addition to protein-
rich/enriched foods of high protein quality, maybe combined
with dietary counselling would seem to be relevant in this pop-
ulation. Also, one could consider leucine supplementation,
which has shown promising results in other studies with healthy
older adults(13,65,66), and can be given in smaller volumes or cap-
sules, compromising appetite to a less degree. Furthermore,
future studies could tackle the heterogeneity of geriatric medical
patients by stratifying according to, for example, the number of
co-morbidities or another measure for severity of illness, or
chose to only include certain sub-groups.
Conclusion
In the present study, no additive effect of PrS during and 12
weeks after hospital admission was found in geriatric medical
patients offered low-intensity RT and isoenergetic placebo sup-
plements. This might be explained by a low difference in total
protein intake between groups of 0·4 g/kg per d during hospital-
isation and 0·2 g/kg per d after discharge. However, based on
LBM gain observed in both groups, the study supports the estab-
lished knowledge of RT as a potent strategy to counteract sarco-
penia. More studies are necessary to establish the importance of
different aspects of the study design, and identification of better
ways to increase the compliance and total protein intake in geri-
atric medical patients would be highly relevant.
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